Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $31.41 USD
Change Today +0.84 / 2.75%
Volume 17.4K
MPSYY On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

morphosys ag-sponsored adr (MPSYY) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/11/14 - $53.89
52 Week Low
03/26/15 - $30.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

morphosys ag-sponsored adr (MPSYY) Related Businessweek News

No Related Businessweek News Found

morphosys ag-sponsored adr (MPSYY) Details

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies for therapeutic applications. The company, together with its partners, develops a therapeutic pipeline of approximately 80 human antibody drug candidates for the treatment of musculoskeletal diseases, Alzheimer‘s disease, and rheumatoid arthritis. It operates therapeutic development programs for drug candidates in cooperation with various biotechnology and pharmaceutical companies, as well as focuses on the development of proprietary therapeutic antibodies in the area of inflammatory diseases and oncology. The company’s proprietary product candidates include MOR103, an antibody that is in phase Ib trial for multiple sclerosis; MOR202, a therapeutic antibody that is in phase I/II trial for the treatment of multiple myeloma; and MOR208, which is in phase II clinical trials for patients suffering from diffuse large B-cell lymphoma. MorphoSys AG has strategic alliances with Novartis AG for the discovery and development of biopharmaceuticals; and Celgene Corporation for the co-development of the cancer program MOR202. The company was founded in 1992 and is headquartered in Martinsried, Germany.

329 Employees
Last Reported Date: 02/18/15
Founded in 1992

morphosys ag-sponsored adr (MPSYY) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €751.2K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €509.6K
Chief Development Officer and Member of Manag...
Total Annual Compensation: €504.5K
Chief Scientific Officer and Member of Manage...
Total Annual Compensation: €499.5K
Compensation as of Fiscal Year 2014.

morphosys ag-sponsored adr (MPSYY) Key Developments

Morphosys AG - Special Call

To discuss the regained rights to MOR202 from Celgene Corporation

Morphosys AG Revises Earnings Guidance for the Year 2015

Morphosys AG revised earnings guidance for the year 2015. For the year, the company now expects revenues of EUR 101 million to EUR 106 million, up from previously EUR 58 million to EUR 63 million, due to the full realization of deferred revenues from the original agreement with Celgene and a one-time payment from Celgene for development costs in 2015. The company now expects earnings before interest and taxes of approximately EUR 9 million to EUR 16 million in 2015 compared to previous LBIT guidance of EUR 20 million to EUR 30 million.

Morphosys AG and Emergent BioSolutions, Inc. Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer

Morphosys AG and Emergent BioSolutions, Inc. announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer (mCRPC). Under the terms of the companies' co-development and commercialization agreement, the achievement of this milestone triggers a payment of USD 5 million by MorphoSys to Emergent. MOR209/ES414 is an immunotherapeutic protein developed by Emergent using its proprietary ADAPTIRTM (modular protein technology) platform. Preclinical in vitro and in vivo studies have shown MOR209/ES414 redirects T-cell cytotoxicity towards cells expressing prostate specific membrane antigen (PSMA), an antigen commonly found on prostate cancer cells. The study will be conducted in two stages. The primary objective of stage 1 is to identify the maximum tolerated dose (MTD) of MOR209/ES414 administered intravenously, with weekly dosing for three months and bi-weekly thereafter, to patients with mCRPC. The secondary objectives are to evaluate the tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, cytokine response, and clinical activity of MOR209/ES414. Within stage 2, the primary objective is to evaluate clinical activity in patients that have or have not received prior chemotherapy, while secondary objectives are to further characterize the safety profile, PK, PD, and immunogenicity of MOR209/ES414. This open-label phase 1 clinical study will be conducted in the U.S. and Australia, with a planned enrollment of up to 130 patients.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MPSYY:US $31.41 USD +0.84

MPSYY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.10 EUR -0.123
Genmab A/S kr516.00 DKK +49.80
ImmunoGen Inc $8.25 USD +0.27
Intrexon Corp $43.00 USD +3.63
XOMA Corp $3.64 USD +0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation MPSYY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.7x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MORPHOSYS AG-SPONSORED ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at